1111 related articles for article (PubMed ID: 16490750)
1. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
2. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
[TBL] [Abstract][Full Text] [Related]
3. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
4. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
5. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
[TBL] [Abstract][Full Text] [Related]
6. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
Kotake S; Udagawa N; Hakoda M; Mogi M; Yano K; Tsuda E; Takahashi K; Furuya T; Ishiyama S; Kim KJ; Saito S; Nishikawa T; Takahashi N; Togari A; Tomatsu T; Suda T; Kamatani N
Arthritis Rheum; 2001 May; 44(5):1003-12. PubMed ID: 11352231
[TBL] [Abstract][Full Text] [Related]
7. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
Mori H; Kitazawa R; Mizuki S; Nose M; Maeda S; Kitazawa S
Histochem Cell Biol; 2002 Mar; 117(3):283-92. PubMed ID: 11914926
[TBL] [Abstract][Full Text] [Related]
8. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
9. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
Kubota A; Hasegawa K; Suguro T; Koshihara Y
J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
[TBL] [Abstract][Full Text] [Related]
11. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
13. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts.
Nakano K; Okada Y; Saito K; Tanaka Y
Arthritis Rheum; 2004 Aug; 50(8):2450-8. PubMed ID: 15334457
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.
Vanderborght A; Linsen L; Thewissen M; Geusens P; Raus J; Stinissen P
J Rheumatol; 2004 Aug; 31(8):1483-90. PubMed ID: 15290725
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
[TBL] [Abstract][Full Text] [Related]
16. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis.
Crotti TN; Ahern MJ; Lange K; Weedon H; Coleman M; Roberts-Thomson PJ; Haynes DR; Smith MD
J Rheumatol; 2003 Nov; 30(11):2319-24. PubMed ID: 14677171
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
18. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Makrygiannakis D; af Klint E; Catrina SB; Botusan IR; Klareskog E; Klareskog L; Ulfgren AK; Catrina AI
Arthritis Rheum; 2006 May; 54(5):1463-72. PubMed ID: 16646024
[TBL] [Abstract][Full Text] [Related]
19. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis.
Wu Y; Liu J; Feng X; Yang P; Xu X; Hsu HC; Mountz JD
Arthritis Rheum; 2005 Oct; 52(10):3257-68. PubMed ID: 16200600
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]